Contract Research Firm Vedic Lifesciences Suggests Program to Help Streamline Clinical Studies

Clinical research organization (CRO) Vedic Lifesciences (Redwood Shores, CA) has introduced a new research model for conducting human clinical studies that the company says will increase efficiency, maximize client resources, and reduce costs for clients.

The new CRO model lets clients take over some of the responsibilities of gathering study data, following training by Vedic staff. Training would include, for instance, methods of collecting human use data using Vedic-prepared systems. Vedic would still perform all final analysis, including essential clinical study documentation, statistical analysis, and report writing, to ensure data is publishable.

Vedic says having companies perform part of the data collection does not jeopardize a study. “The data collected by the companies are in the format, forms, instruments, and systems that are prepared by Vedic,” says marketing manager Shefali Roy. “This does not compromise the quality or the credibility of the data, as this data is finally sent to Vedic for final analysis.” Also, he adds, collection of blood or body fluid samples would only be done by a trained team.

Vedic says this program will “ensure optimum utilization of the limited resources at some client companies,” as well as “facilitate organized collection of reliable and credible data during clinical studies, at reduced costs” because companies would take over some of the responsibilities.

Roy says that what sets the ACElerator program apart from other CRO programs that also encourage companies and CROs to share responsibilities is that none of the other programs “train the sponsor team for future clinical trials to be done independently.” He says, “By getting the sponsor team trained by an expert CRO team, the volume of work outsourced in the future by the sponsor can probably be reduced. The sponsor can also have a long-term partnership with the CRO that helps reduce the overall outsourcing cost.”

“This model is a definite win-win situation,” added Jayesh Chaudhary, Vedic CEO. “Clients can proactively adopt this strategy to become self-reliant and be well-equipped for their future clinical trial needs. This will surely provide them a distinct edge over their competitors.”

“This model helps utilize all the resources available optimally to ensure faster completion of the study. Quick start-up, continuous monitoring and data collection leads to completion of the study as per the decided and agreed timelines, helping companies take the product faster to the market, without compromising the quality and the credibility of the data collected or the study conducted,” Roy says.